Population-level prevalence of detectable HIV viremia in people who inject drugs (PWID) in Ukraine: Implications for HIV treatment and case finding interventions.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 22 03 2023
accepted: 13 08 2023
medline: 30 10 2023
pubmed: 26 10 2023
entrez: 26 10 2023
Statut: epublish

Résumé

Achievement of viral load suppression among people living with HIV is one of the most important goals for effective HIV epidemic response. In Ukraine, people who inject drugs (PWID) experience the largest HIV burden. At the same time, this group disproportionally missed out in HIV treatment services. We performed a secondary data analysis of the national-wide cross-sectional bio-behavioral surveillance survey among PWID to assess the population-level prevalence of detectable HIV viremia and identify key characteristics that explain the outcome. Overall, 11.4% of PWID or 52.6% of HIV-positive PWID had a viral load level that exceeded the 1,000 copies/mL threshold. In the group of HIV-positive PWID, the detectable viremia was attributed to younger age, monthly income greater than minimum wage, lower education level, and non-usage of antiretroviral therapy (ART) and opioid agonistic therapy. Compared with HIV-negative PWID, the HIV-positive group with detectable viremia was more likely to be female, represented the middle age group (35-49 years old), had low education and monthly income levels, used opioid drugs, practiced risky injection behavior, and had previous incarceration history. Implementing the HIV case identification and ART linkage interventions focused on the most vulnerable PWID sub-groups might help closing the gaps in ART service coverage and increasing the proportion of HIV-positive PWID with viral load suppression.

Identifiants

pubmed: 37883454
doi: 10.1371/journal.pone.0290661
pii: PONE-D-23-05654
pmc: PMC10602286
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0290661

Subventions

Organisme : PEPFAR
Pays : United States

Informations de copyright

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
BMC Infect Dis. 2019 Dec 27;19(1):1084
pubmed: 31881859
Am J Drug Alcohol Abuse. 2008;34(2):161-70
pubmed: 18293232
Sci Transl Med. 2017 Dec 13;9(420):
pubmed: 29237762
Am J Public Health. 2015 Jul;105(7):e5-16
pubmed: 25973818
Am J Orthod Dentofacial Orthop. 2014 Jul;146(1):127-9
pubmed: 24975008
BMC Infect Dis. 2021 May 18;21(1):448
pubmed: 34006230
Medicine (Baltimore). 2018 Oct;97(43):e13016
pubmed: 30412140
PLoS One. 2015 Jul 06;10(7):e0131353
pubmed: 26147987
Rev Saude Publica. 2008 Dec;42(6):992-8
pubmed: 19009156
Lancet. 1999 May 15;353(9165):1657-61
pubmed: 10335785
BMC Infect Dis. 2019 Feb 15;19(1):169
pubmed: 30770728
BMC Med Res Methodol. 2019 Oct 29;19(1):202
pubmed: 31664912
PLoS One. 2020 Dec 31;15(12):e0244572
pubmed: 33382768
PLoS One. 2012;7(5):e38335
pubmed: 22719814
J Int Assoc Provid AIDS Care. 2017 Mar/Apr;16(2):125-132
pubmed: 28090799
J Virol Methods. 2009 Dec;162(1-2):218-22
pubmed: 19729037
AIDS. 2018 Nov 28;32(18):2807-2819
pubmed: 30289816
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Lancet HIV. 2021 Sep;8(9):e544-e553
pubmed: 34331860
Drug Alcohol Depend. 2020 Jan 1;206:107670
pubmed: 31711873
Curr Opin HIV AIDS. 2012 Mar;7(2):99-105
pubmed: 22227585
Annu Rev Med. 2020 Jan 27;71:347-360
pubmed: 31652410
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):288-295
pubmed: 30312275
HIV AIDS (Auckl). 2021 May 14;13:513-526
pubmed: 34017201
J Urban Health. 2010 Jul;87(4):592-602
pubmed: 20177974
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
AIDS. 2015 May 15;29(8):965-73
pubmed: 25915170

Auteurs

Yana Sazonova (Y)

PEPFAR Coordination Office in Ukraine, Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.

Roksolana Kulchynska (R)

Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.

Marianna Azarskova (M)

Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.

Mariia Liulchuk (M)

State Institution "The L.V. Gromashevskij Institute of Epidemiology and Infectious Diseases of NAMS of Ukraine", Kyiv, Ukraine.

Tetiana Salyuk (T)

Monitoring and Evaluation Unit, ICF "Alliance for Public Health", Kyiv, Ukraine.

Ivan Doan (I)

Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.

Ezra Barzilay (E)

Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH